黄热病毒保护性抗体研究进展  

Research progress in protective antibodies against yellow fever virus

作　　者：索星星 迟航 邓永强 韩晓东[1] SUO Xingxing;CHI Hang;DENG Yongqiong;HAN Xiaodong(College of Life Sciences,Inner Mongolia Agricultural University,Hohhot 010018,China;State Key Laboratory of Pathogen and Biosecurity,Academy of Military Medical Sciences,Academy of Military Sciences,Beijing 100071,China)

机构地区：[1]内蒙古农业大学生命科学学院,呼和浩特010011 [2]军事科学院军事医学研究院,病原微生物生物安全全国重点实验室,北京100071

出　　处：《军事医学》2024年第8期636-640,共5页Military Medical Sciences

基　　金：内蒙古自治区自然科学基金面上项目(2022SHZR1769)。

摘　　要：黄热病毒(YFV)是世界上最重要的蚊媒黄病毒之一,每年造成约20万例感染和3万例死亡,严重威胁人民健康和经济发展。目前,临床上尚无批准的YFV特异性治疗药物。抗体药物安全性高、靶向性强、治疗显著,是病毒性传染病预防和治疗的有效手段之一。该文阐述了近年国内外研发的YFV保护性抗体及发展方向,以期为研制高效安全的YFV特异性治疗药物提供参考。Yellow fever virus(YFV)is one of the most important mosquito-borne flaviviruses in the world,causing about 200,000 infections and 30,000 deaths each year,with serious impacts on human health and economic development.Currently,there are no approved specific anti-viral drugs for YFV infection.On the other hand,antibody drugs are safe,highly targeted and effective,making them one of the most effective means of prevention and treatment of viral infectious diseases.This review summarizes the characteristics of YFV and the recent advances in the development of protective antibodies against YFV,and predict the priorities of future research and development of protective antibodies,which may offer a new line of thought for subsequent development of yellow fever virus-specific drugs.

关 键 词：黄热病毒 包膜蛋白 中和抗体 

分 类 号：R373[医药卫生—病原生物学]